Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction
Abstract
Importance
The PCSK9 inhibitor evolocumab reduced major vascular events in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial, yet the types and sizes of myocardial outcomes in FOURIER have not been previously explored.Objective
To assess the types and sizes of myocardial infarction (MI) and the effect of evolocumab on MI by subtype.Design, Setting, and...
Paper Details
Title
Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction
Published Date
Jul 1, 2020
Journal
Volume
5
Issue
7
Pages
787 - 787
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History